ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Long-Term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)

This study is ongoing, but not recruiting participants.

Sponsored by: Zymenex A/S
Information provided by: Zymenex A/S
ClinicalTrials.gov Identifier: NCT00633139
  Purpose

This is a single center, open-label study of patients with late infantile MLD. All patients were previous treated 26 weeks in the phase I trial (EudraCT number: 2006-005341-11). All patients will be offered continuing treatment in this study and will in this protocol receive 13 infusions, whereby the patients total have had 27 infusions of Metazym. One infusion will be given every other week. After a total of 52 weeks of treatment the subjects will continue treatment in a compassionate use protocol. Safety (AE/SAE) will be monitored at every visit. The efficacy observed during the first 26 weeks of treatment in the phase I trial (EudraCT number: 2006-005341-11) will be studied further during totally 1 year of treatment. The myelin recovery (CNS and PNS) and functional capacity will be evaluated after this long-term treatment.


Condition Intervention Phase
Late Infantile Metachromatic Leukodystrophy
Drug: Metazym
Phase II

Genetics Home Reference related topics:   metachromatic leukodystrophy  

MedlinePlus related topics:   Leukodystrophies  

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Non-Randomized, Open Label, Uncontrolled, Factorial Assignment, Efficacy Study
Official Title:   A Single Center, Open-Label, Non-Randomized, Uncontrolled, Multiple-Dose Study of the Efficacy and Long-Term Safety of Metazym (Recombinant Human Arylsulfatase A or rhASA) for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy

Further study details as provided by Zymenex A/S:

Primary Outcome Measures:
  • Relative change in GMFM after 52 weeks of treatment Absolute change in Mullen's Scales of Early Learning, after 52 weeks of treatment. [ Time Frame: 52 weeks of tratment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in CSF biomarker after 52 weeks of treatment with focus on reduction of sulfatid. [ Time Frame: After 52 weeks of treatment ] [ Designated as safety issue: No ]

Enrollment:   12
Study Start Date:   February 2008
Estimated Study Completion Date:   December 2008
Estimated Primary Completion Date:   September 2008 (Final data collection date for primary outcome measure)

Intervention Details:
    Drug: Metazym
    The three dose levels will be given as repeated doses. Patients in each cohort will receive one dose of enzyme every other week. Dosing will be performed as follows: Cohort 1: 50 U/kg, Cohort 2: 100 U/kg and Cohort 3: 200 U/kg. After a total of 52 weeks the subjects will continue treatment in a compassionate use protocol. Safety (AE/SAE) will be monitored at every visit. The dose will be adjusted monthly to account for changes in body weight.
  Eligibility
Ages Eligible for Study:   1 Year to 5 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Subject's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject)
  • The subject and his/her guardian(s) must have the ability to comply with the clinical protocol

Exclusion Criteria:

  • Spasticity so severe to inhibit transportation
  • Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical condition that, in the opinion of the Investigator, would preclude participation in the trial
  • Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial
  • Use of any investigational product other than rhASA within 30 days prior to study enrolment or currently enrolled in another study which involves clinical investigations
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00633139

Locations
Denmark, Hvidovre
PhaseOneTrials A/S    
      Copenhagen, Hvidovre, Denmark, 2650

Sponsors and Collaborators
Zymenex A/S

Investigators
Principal Investigator:     Allan M Lund, MD     Rigshospitalet, Denmark    
  More Information

Sponsors homepage  This link exits the ClinicalTrials.gov site
 

Responsible Party:   Zymenex ( Jens Fogh )
Study ID Numbers:   rhASA-03, rhASA-03, EudraCT number: 2007-006345-40
First Received:   February 29, 2008
Last Updated:   February 29, 2008
ClinicalTrials.gov Identifier:   NCT00633139
Health Authority:   Denmark: Danish Dataprotection Agency;   Denmark: Danish Medicines Agency;   Denmark: Ethics Committee

Keywords provided by Zymenex A/S:
Metazym  
Late infantile  
Metachromatic leukodystrophy  
Long-term safety  

Study placed in the following topic categories:
Lipid Metabolism, Inborn Errors
Sphingolipidoses
Metabolic Diseases
Leukodystrophy, Metachromatic
Demyelinating Diseases
Lysosomal Storage Diseases
Sphingolipidosis
Central Nervous System Diseases
Demyelinating diseases
Brain Diseases
Leukodystrophy
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Metachromatic leukodystrophy
Brain Diseases, Metabolic, Inborn
Lipidoses
Metabolic disorder
Congenital Abnormalities
Lipid Metabolism Disorders

Additional relevant MeSH terms:
Lysosomal Storage Diseases, Nervous System
Nervous System Diseases
Sulfatidosis
Nutritional and Metabolic Diseases
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hereditary Central Nervous System Demyelinating Diseases

ClinicalTrials.gov processed this record on May 08, 2008